Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 4:2020:2967260.
doi: 10.1155/2020/2967260. eCollection 2020.

The Clinical Significance of High Antimicrobial Resistance in Community-Acquired Urinary Tract Infections

Affiliations

The Clinical Significance of High Antimicrobial Resistance in Community-Acquired Urinary Tract Infections

Maria G Zavala-Cerna et al. Can J Infect Dis Med Microbiol. .

Abstract

Background: Urinary tract infections (UTIs) affect up to 150 million individuals annually worldwide, mainly due to Escherichia coli (E. coli) and Klebsiella. The emergence and spread of multidrug-resistant (MDR) bacteria are increasing, representing one of the biggest threats for human health. The objective of our study was to describe antimicrobial patterns of resistance and identify risk factors associated with MDR uropathogens.

Methods: We conducted a cross-sectional study in 296 patients with community-acquired UTI who underwent clinical and microbiologic analysis, and clinical associations to MDR uropathogens were investigated. Findings. Microbiological analysis included E. coli (55%), ESBL-E. coli (26%), Enterococcus (6%), Klebsiella (5%), and others (8%). Higher frequencies of MDR bacteria were found among ESBL-E. coli, with resistance to ampicillin (100%), ceftriaxone (96%), gentamicin (57%), ciprofloxacin (89%), and TMP/SMX (53%). However, they were sensitive to fosfomycin (6.6%), nitrofurantoin (1.3%), and carbapenems (0%). Fosfomycin MIC90 for ESBL-E. coli was 5.78 μg/mL. The only clinical variable with significant association to ESBL producers was the presence of comorbidities: hypertension and type 2 diabetes mellitus with an OR (95%CI) of 2.5(1.3 - 4.9)(p < 0.01) and 2.8(1.2 - 6.7)(p < 0.05), respectively.

Conclusions: In the majority of cases, resistance rates to commonly prescribed antimicrobials in UTIs were high, except for fosfomycin, nitrofurantoin, and carbapenems. To provide appropriate treatment, both the identification of risk factors and the uropathogen would be important. An active surveillance in UTIs in the community is required since the proportion of ESBL producers is increasing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Resistance patterns in isolated uropathogens from community-associated uncomplicated cystitis to optimal treatment options according to IDSA guidelines and the European society for microbiology and infectious diseases.

Similar articles

Cited by

References

    1. Foxman B. The epidemiology of urinary tract infection. Nature Reviews Urology. 2010;7(12):653–660. doi: 10.1038/nrurol.2010.190. - DOI - PubMed
    1. Ferry S. A., Holm S. E., Stenlund H., Lundholm R., Monsen T. J. Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project. Scandinavian Journal of Primary Health Care. 2007;25(1):49–57. doi: 10.1080/02813430601183074. - DOI - PMC - PubMed
    1. Nicolle L. E. Asymptomatic bacteriuria-important or not? New England Journal of Medicine. 2000;343(14):1037–1039. doi: 10.1056/nejm200010053431409. - DOI - PubMed
    1. Geerlings S. E. Clinical presentations and epidemiology of urinary tract infections. Microbiology Spectrum. 2016;4(5) doi: 10.1128/microbiolspec.uti-0002-2012. - DOI - PubMed
    1. Yeganeh-Sefidan F., Ghotaslou R., Akhi M., et al. Fosfomycin, interesting alternative drug for treatment of urinary tract infections created by multiple drug resistant and extended spectrum beta-lactamase producing strains. Iranian Journal of Microbiology. 2016;8(2):125–131. - PMC - PubMed

LinkOut - more resources